pharmachologic effect
Bronchodilator, methylxanthine derivative; inhibits phosphodiesterase, increases the accumulation of cyclic adenosine monophosphate (cAMP) in tissues, blocks adenosine (purine) receptors; reduces the flow of calcium ions through the channels of cell membranes, reduces the contractile activity of smooth muscles.
Relaxes the bronchial muscles, stimulates the respiratory center and improves alveolar ventilation, which ultimately leads to a reduction in the severity and frequency of apnea episodes.
It has a stimulating effect on the activity of the heart, increases the strength and frequency of heart contractions, increases coronary blood flow and myocardial oxygen demand. Reduces the tone of blood vessels (mainly those of the brain, skin and kidneys). It has a peripheral venodilating effect, reduces pulmonary vascular resistance, and lowers pressure in the pulmonary circulation. Increases renal blood flow and has a moderate diuretic effect. Expands extrahepatic bile ducts.
Stabilizes mast cell membranes, inhibits the release of mediators of allergic reactions.
Inhibits platelet aggregation (suppresses platelet activating factor and prostaglandin E2 alpha), increases the resistance of red blood cells to deformation (improves the rheological properties of blood), reduces thrombus formation and normalizes microcirculation.
It has a tocolytic effect, increases the acidity of gastric juice. When used in large doses, it has an epileptogenic effect.
Pharmacokinetics
Bioavailability and absorption kinetics depend on the dosage form of the drug. Bioavailability for liquid dosage forms is 90-100%. The time to reach the maximum concentration of the drug in plasma with intravenous administration of 0.3 g is 15 minutes, the maximum concentration of the drug in the blood is 7 mcg/ml. The volume of distribution is in the range of 0.3-0.7 l/kg (30-70% of “ideal” body weight), with an average of 0.45 l/kg. Communication with plasma proteins in adults - 60%, in newborns - 36%, in patients with liver cirrhosis - 36%. Penetrates into breast milk (10% of the dose taken), through the placental barrier (the concentration in the fetal blood serum is slightly higher than in the maternal serum).
Aminophylline exhibits bronchodilating properties in concentrations of 10-20 mcg/ml. Concentrations above 20 mg/ml are toxic. The stimulating effect on the respiratory center is realized at a lower content of the drug in the blood - 5-10 mcg/ml.
Metabolized at physiological pH values with the release of free theophylline, which is further metabolized in the liver with the participation of several cytochrome P450 isoenzymes. As a result, 1,3-dimethyluric acid (45-55%) is formed, which has pharmacological activity, but is 1-5 times inferior to theophylline. Caffeine is an active metabolite and is formed in small quantities, with the exception of premature newborns and children under 6 months, in whom, due to the extremely long half-life of caffeine, its significant accumulation in the body occurs (up to 30% of that for aminophylline).
In children over 3 years of age and in adults, the phenomenon of caffeine accumulation is absent.
The half-life in newborns and children under 6 months is more than 24 hours; in children older than 6 months. — 3.7 hours; in adults - 8.7 hours; for “smokers” (20-40 cigarettes per day) - 4-5 hours (after quitting smoking, pharmacokinetics normalize after 3-4 months); in adults with chronic obstructive pulmonary disease, pulmonary heart disease and pulmonary heart failure - over 24 hours. Excreted by the kidneys. In newborns, about 50% of theophylline is excreted unchanged in the urine versus 10% in adults, which is associated with insufficient activity of liver enzymes.
Pharmacological effects
The main effect of the drug is antispasmodic. However, it also has other effects on the human body, namely tocolytic, diuretic and bronchodilator.
According to the Vidal classifier, Eufillin is included in the pharmacological group of phosphodiesterase inhibitors.
What does Eufillin help with? Indications for use
Indications for use of the drug Eufillin may vary slightly depending on the form of release. Tablets are most often prescribed for:
- Bronchial asthma of varying severity.
- Chronic obstructive pulmonary disease.
- Paroxysmal attacks of apnea at night.
- Right ventricular heart failure.
- Emphysema.
The injection form of the drug is used for:
- Cerebrovascular insufficiency of the brain (the drug is used in combination with other drugs and helps reduce intracranial pressure).
- Pulmonary hypertension.
- Left ventricular heart failure (also used in combination with a number of other drugs).
- For diseases of the respiratory system accompanied by spasm and broncho-obstructive syndrome (COPD, emphysema, bronchial asthma).
Contraindications
Hypersensitivity to the drug (including other xanthine derivatives: caffeine, pentoxifylline, theobromine), severe arterial hypotension or hypertension, paroxysmal tachycardia, extrasystole, myocardial infarction with cardiac arrhythmias, epilepsy, increased convulsive readiness, hypertrophic obstructive cardiomyopathy , thyrotoxicosis, pulmonary edema, severe coronary insufficiency, liver and/or renal failure, hemorrhagic stroke, retinal hemorrhage, recent history of bleeding.
Carefully
Severe coronary insufficiency (acute phase of myocardial infarction, angina pectoris), widespread vascular atherosclerosis, hypertrophic obstructive cardiomyopathy, frequent ventricular extrasystole, increased convulsive readiness, liver and/or renal failure, peptic ulcer of the stomach and duodenum (history), bleeding from gastrointestinal tract in a recent history, uncontrolled hypothyroidism (possibility of cumulation) or thyrotoxicosis, prolonged hyperthermia, gastroesophageal reflux, prostatic hypertrophy, children under 14 years of age, old age (over 55 years).
Prescribe with caution simultaneously with anticoagulants, with other theophylline and purine derivatives.
Use during pregnancy and breastfeeding
If necessary, prescribing the drug during pregnancy should be compared
expected benefit to the mother and potential risk to the fetus.
If it is necessary to use the drug during lactation, breastfeeding should be discontinued.
Newborns whose mothers received aminophylline during pregnancy (especially the third trimester) require medical supervision to monitor possible symptoms of methylxanthine intoxication.
Eufillin instructions for use, treatment, indications for use
EUPHYLLINE
Euphyllinum (CIS)
Synonyms of Eufillin. Aminophylline - Aminophyllinum; Diaphylline - Diaphyllin (Ven.); Novfillin - Novphyllin (Bol.); Syntophyllin - Synthophyllin (Czech).
Eufillin dosage forms.
Eufillin is a combination drug. Composition: theophylline - 80%, 1,2-ethylenediamine - 20%. Available in powders, tablets of 0.15 g in packs of 30 pieces, ampoules of 10 ml of 2.4% solution and 1 ml of 24% solution in packs of 10 pieces. The highest doses orally and into the rectum are: VRD - 0.5 g, VSD - 1.5 g.
Eufillin description of medicinal properties.
The drug has an antispasmodic and vasodilator effect. Eufillin lowers blood pressure, improves blood supply to the heart muscle and internal organs, stimulates cardiac activity and increases the heart's need for oxygen. The drug relieves muscle spasms of the bronchi, intestines, urinary and biliary tracts, has some diuretic effects, and somewhat stimulates the central nervous system. Eufillin can accumulate (cumulate) in the body.
Eufillin indications for use.
The drug is used for bronchial asthma, bronchospasms, pulmonary edema, cardiac asthma, angina pectoris, myocardial infarction, stroke accompanied by cerebral edema, edema of cardiac and renal origin, intestinal, renal and hepatic colic.
Eufillin instructions for use.
The drug is prescribed orally, into the rectum (rectally), intramuscularly and intravenously. The drug is not administered subcutaneously, as it causes severe tissue irritation. Take 1 tablet orally 2-3 times a day after meals. 0.3 g is administered into the rectum in suppositories or microenemas. Microenemas are prepared at the rate of 0.25-0.4 g per 20-25 ml of warm water. For children, the drug is prescribed in smaller doses, calculated according to an age scale or using special formulas.
Eufillin side effects and complications.
If taken orally, nausea, vomiting, diarrhea, and abdominal pain may develop. Headaches, increased excitability, anxiety, sleep disturbances, palpitations, decreased blood pressure (hypotension), and skin rashes may occur. When used in suppositories, irritation of the rectal mucosa is possible.
Eufillin contraindications.
The drug is not prescribed for low blood pressure, paroxysmal palpitations (paroxysmal tachycardia), and extraordinary contractions of the heart (extrasystoles). Eufillin should not be used in the acute period of myocardial infarction, with sclerosis of the heart vessels (coronary sclerosis), peptic ulcers associated with increased production of gastric juice. Eufillin is absolutely contraindicated for children under 6 months. The drug should be prescribed with caution to children under 14 years of age.
Storage of Eufillin.
The drug should be stored in a well-closed container, protected from light. The shelf life of the powder is 2 years, tablets - 5 years, ampoules of 2.4% solution - 2 years, ampoules of 24% solution - 1 year.
special instructions
Use caution when consuming large amounts of caffeine-containing foods or drinks during treatment.
Elderly patients are recommended to reduce the dose of the drug due to its slow elimination from the body.
Smoking patients are advised to increase the dose due to the accelerated elimination of the drug from the body.
Before use, the drug solution must be warmed to body temperature.
Impact on the ability to drive vehicles and machinery.
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Directions for use and doses
Adults are injected into a vein slowly (over 4-6 minutes) with 5-10 ml of a solution with a concentration of 24 mg/ml (0.12-0.24 g), which is pre-diluted in 10-20 ml of isotonic sodium chloride solution. If palpitations, dizziness, or nausea occur, the rate of administration is slowed down or switched to drip administration, for which 10-20 ml of a solution with a concentration of 24 mg/ml (0.24-0.48 g) is diluted in 100-150 ml of isotonic sodium chloride solution; administered at a rate of 30-50 drops per minute. Eufillin is administered parenterally up to 3 times a day, for no more than 14 days.
Higher doses of aminophylline for adults into a vein: single - 0.25 g, daily - 0.5 g.
Children under 14 years of age are advised to use the drug with caution due to possible side effects.
However, if necessary, children are administered aminophylline intravenously at a single dose of 2-3 mg/kg, preferably by drip.
Higher doses for children intravenously: single - 3 mg/kg, daily - up to 3 months of age. -0.03-0.06 g,
from 4 to 12 months. - 0.06-0.09 g,
from 2 to 3 years - 0.09-0.12 g,
from 4 to 7 years - 0.12-0.24 g,
from 8 to 18 years - 0.25-0.5 g.
Eufillin 2.4% 5 ml No. 10 amp.
Euffilin 2.4% 5ml No. 10 ampoules
Trade name Eufillin International nonproprietary name Aminophylline Dosage form Solution for intravenous administration 2.4% 5 ml Composition 5 ml of solution contains the active substance - aminophylline for injection in terms of anhydrous substance 120 mg, excipient - water for injection. Description Transparent colorless or slightly yellowish liquid
Pharmacotherapeutic group Other drugs for the treatment of obstructive airway diseases for systemic use. Xanthines. ATC code R03DA05 Pharmacological properties Pharmacokinetics After intravenous administration, it is 60% bound to blood proteins (with liver cirrhosis, the proportion of the protein-bound fraction decreases to 35%, and in newborns this figure is 36%). Penetrates well through histohematic barriers and is evenly distributed in the blood, extracellular fluid and muscle tissue. Does not accumulate in adipose tissue. Penetrates through the placental barrier and into mother's milk. The volume of distribution is 0.3-0.7 l/kg (average 0.45 l/kg). The bronchodilator effect is manifested when its concentration in the blood plasma is maintained at a level of 10-20 mcg/ml. Concentrations of aminophylline in plasma above 20 mcg/ml are toxic. Subjected to intensive metabolism in the liver (about 90%), under the influence of methylases and cytochrome P450, it is partially converted into caffeine. In children under 3 years of age, the concentration of caffeine can reach 30% of the concentration of aminophylline. In adults and children over 3 years of age, the phenomenon of caffeine accumulation is not observed. It is excreted by the kidneys, 10% in adults and about 50% in children - unchanged. The half-life of aminophylline (T1/2) in newborns and children under 6 months is >24 hours; in children over 6 months - 3.7 hours; in adults who do not suffer from bronchopulmonary pathology - 8.7 hours. In persons who smoke 20-40 cigarettes per day, T1/2 is shortened to 4-5 hours. In persons with obstructive pulmonary diseases, heart failure and cor pulmonale, the half-elimination period nation is extended to 24 hours.
Pharmacodynamics Has bronchodilating, vasodilating, antispasmodic, tocolytic and diuretic effects. The mechanism of action is associated with a blocking effect on type A2 purine receptors of smooth muscle cells. Eufillin causes relaxation of the smooth muscles of the bronchi, coronary, cerebral and pulmonary vessels, the muscles of the gastrointestinal tract and biliary tract. Eufillin reduces the hyperreactivity of the respiratory tract in response to the entry of allergens into them. Eufillin increases the contractility of skeletal muscles (including respiratory muscles - the diaphragm, intercostal muscles) and slows down the development of their fatigue. It has a stimulating effect on the heart muscle, increasing the force of its contraction (positive inotropic effect). The dilation of the vessels of the renal glomeruli is accompanied by an increase in blood filtration in the kidneys and a short-term increase in diuresis. Stimulates the respiratory center of the medulla oblongata, improves alveolar ventilation, and causes a reduction in the frequency and severity of episodes of sleep apnea. Eufillin suppresses the rhythmic contractions of the pregnant uterus, increases the secretion of hydrochloric acid in the stomach, and slightly reduces the ability of platelets to adhesion and aggregation. Indications for use - broncho-obstructive syndrome in bronchial asthma, bronchitis, emphysema, cardiac asthma (mainly for the relief of attacks) - cerebrovascular accident of the ischemic type (as part of combination therapy) - hypertension in the pulmonary circulation - left ventricular failure with bronchospasm and disorder breathing according to the Cheyne-Stokes type (as part of combination therapy) - status asthmaticus (additional therapy)
Method of administration and dosage Adults: administered intravenously slowly (over 4-6 minutes) 5-10 ml of a 24 mg/ml solution (0.12-0.24 g), which is pre-diluted in 10-20 ml of isotonic sodium chloride solution . If palpitations, dizziness, or nausea occur, the rate of administration is slowed down or switched to drip administration, for which 10-20 ml of a 24 mg/ml solution (0.24-0.48 g) is diluted in 100-150 ml of isotonic sodium chloride solution; administered at a rate of 30-50 drops per minute. Eufillin is administered parenterally up to 3 times a day, for no more than 14 days. Higher doses of aminophylline for adults: single - 0.25 g, daily - 0.5 g. In emergency conditions, adults are administered intravenously at a dose of 6 mg/kg, diluted in 10-20 ml of 0.9% NaCl solution, administered slowly over at least 5 min. For status asthmaticus, intravenous drip administration is indicated - 720-750 mg. The drug is not recommended for children under 14 years of age due to side effects. Higher doses for children intravenously: single - 3 mg/kg, daily - 0.25-0.5 g.
Side effects - dizziness, headache, anxiety, sleep disturbances, tremors, convulsions, a feeling of flushing in the face, increased sweating - chest pain, palpitations (tachypnea), cardiac arrhythmia, with rapid intravenous administration - an attack of angina, a sharp decrease in blood pressure - anorexia, nausea, vomiting, gastroesophageal reflux, heartburn, exacerbation of peptic ulcer, diarrhea - albuminuria, hematuria, increased diuresis - allergic skin reactions: urticaria, exfoliative dermatitis, fever - in some cases - hypoglycemia - phlebitis at the injection site. Side effects decrease with decreasing dosage of the drug.
Contraindications - hypersensitivity to aminophylline and other methylxanthines - acute phase of myocardial infarction - severe arterial hypotension and hypertension - severe tachyarrhythmia - hemorrhagic stroke - retinal hemorrhage - severe dysfunction of the liver and/or kidneys - epilepsy - taking ephedrine (in children) - children up to 14 years old
Drug interactions Ephedrine, β-agonists, caffeine and furosemide enhance the effect of the drug. In combination with phenobarbital, phenytoin, rifampicin, isoniazid, carbamazepine and sulfinpyrazone, acceleration of aminophylline metabolism is observed, which is accompanied by a decrease in its effect and may require an increase in the doses of the drug used. In people who smoke (20-40 cigarettes per day), an acceleration of aminophylline metabolism is also observed. When prescribed in combination with macrolide antibiotics, lincomycin, allopurinol, cimetidine, isoprenaline, combined oral contraceptives, disulfiram, fluvoxamine, viloxazine, influenza vaccines and beta-blockers, the elimination of the drug slows down, which is accompanied by an increase in its plasma concentration and may require a dose reduction. If aminophylline is used together with fluoroquinolones, the dose of aminophylline is reduced to 1/4 of the usually recommended dose. When xanthines are administered together with benzylpenicillin, its chemical inactivation occurs. Eufillin weakens the therapeutic effects of lithium salts, pyridoxine and β-blockers. In turn, the administration of β-blockers weakens the bronchodilator effect of aminophylline. When taking aminophylline together with β-adrenergic agonists, glucocorticosteroids and diuretics, the risk of developing hypoglycemia increases. Eufillin increases the likelihood of developing undesirable effects of mineralocorticosteroids (hypernatremia), fluorinated derivatives of anesthetics (ventricular arrhythmias), and drugs that excite the central nervous system (neurotoxicity). The combined administration of xanthines with cardiac glycosides is dangerous due to the development of intoxication by the latter. Compatible with antispasmodics, do not use in combination with other xanthine derivatives. When used simultaneously with macrolide antibiotics, lincomycin, allopurinol, cimetidine, isoprenaline, enoxacin, small doses of ethanol, disulfiram, fluoroquinolones, recombinant interferon alpha, methotrexate, mexiletine, propafenone, tibeabendazole, ticlopidine, verapamil and with influenza vaccination The intensity of action of aminophylline may increase, which may require a reduction in its dose. Pharmaceutically incompatible with acid solutions, glucose, fructose and levulose solutions. When preparing for infusion, the pH of the solutions used should be taken into account.
Special instructions Use in geriatrics The use of aminophylline in persons over 60 years of age should be carried out in low doses. The drug is prescribed with caution, under constant medical supervision, to patients: - with severe impairment of liver and kidney function (liver and/or renal failure) - with a recent history of bleeding from the gastrointestinal tract - with severe coronary insufficiency - with widespread vascular atherosclerosis - with frequent ventricular extrasystoles - with increased convulsive readiness - with uncontrolled hypothyroidism (possibility of cumulation) or thyrotoxicosis - with prolonged hyperthermia - with gastroesophageal reflux - with prostatic hypertrophy Use with caution, under constant medical supervision is necessary in patients with severe arterial hypertension, hyperthyroidism, tachycardia, hypertrophic obstructive cardiomyopathy, gastric and duodenal ulcers (history). In case of chronic heart failure, liver failure, viral infections or pneumonia, a reduction in aminophylline doses is required. Eufillin is not used simultaneously with other xanthine derivatives. During the treatment period, you should avoid consuming foods and drinks containing xanthine derivatives (strong tea, coffee, chocolate, cocoa, mate). Pregnancy and lactation The use of aminophylline during pregnancy can lead to the creation of potentially dangerous concentrations of theophylline and caffeine in the body of the newborn and fetus. Newborns whose mothers received aminophylline during pregnancy (especially the third trimester) require medical supervision to monitor possible symptoms of methylxanthine intoxication. Prescribing the drug during pregnancy and lactation requires an assessment of the potential risk to the child and is carried out only for extreme health conditions. Breastfeeding should be discontinued while taking the drug. Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms Considering the side effects of the drug, during the treatment period you should refrain from driving vehicles and engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions
Overdose Symptoms: occur when the drug concentration in plasma is more than 20 mcg/ml. Characterized by prolonged vomiting, diarrhea, facial flushing, arrhythmia, agitation, photophobia, tremor and convulsions. When blood levels exceed 40 mcg/ml, coma develops. Treatment: assistance measures include discontinuation of the drug, forced diuresis with the use of loop diuretics: furosemide, trosemide; at levels more than 50 mcg/ml, hemosorption and plasmapheresis are indicated. Hemodialysis or peritoneal dialysis are ineffective. For convulsive syndrome - intramuscular administration of diazepam (barbiturates are contraindicated!). To relieve arrhythmias, intravenous lidocaine or verapamil is used. For vomiting, intravenous metoclopramide or ondansetron is used. The use of etaprazine or other antipsychotics as antiemetics is contraindicated! As a specific antidote for aminophylline intoxication, intravenous jet administration of riboxin (inositol) in an isotonic sodium chloride solution is used (glucose or dextrose solutions should not be used for dilution).
Release form and packaging Solution in ampoules of 5 ml. 10 ampoules each along with instructions for use in the state and Russian languages and a knife for opening ampoules in a cardboard box. It is allowed to include instructions for medical use in the state and Russian languages in a group package in a quantity corresponding to the number of boxes. 5 ampoules are placed in a liner made of polyvinyl chloride film. 2 inserts with ampoules, along with a knife for opening ampoules and with instructions for medical use in the state and Russian languages, are placed in a pack of cardboard for consumer packaging. In the case of using ampoules with a break ring or a notch and a break point, inserting a knife to open the ampoules is not provided. 10 ampoules, together with a knife for opening ampoules and with instructions for medical use in the state and Russian languages, are placed in a pack with a cardboard insert for fixing ampoules made of cardboard for consumer packaging. Storage conditions : Protected from light, at a temperature not exceeding 25°C. Keep out of the reach of children!
Shelf life: 2 years Do not use after expiration date. Conditions for dispensing from pharmacies By prescription
Side effect
From the nervous system:
dizziness, headache, insomnia, agitation, anxiety, irritability, tremor, convulsions.
From the cardiovascular system
: palpitations, tachycardia (including in the fetus when taken by a pregnant woman in the third trimester), arrhythmias, decreased blood pressure, cardialgia, increased frequency of angina attacks.
From the digestive system:
gastralgia, nausea, vomiting, gastroesophageal reflux, heartburn, exacerbation of peptic ulcer, diarrhea, with long-term use - loss of appetite.
Allergic reactions
: skin rash, skin itching, fever, exfoliative dermatitis.
Other:
chest pain, tachypnea, feeling of “hot flashes” in the face, albuminuria, hematuria, hypoglycemia, increased diuresis, increased sweating.
Side effects decrease with decreasing dosage of the drug.
Local reactions:
compaction, hyperemia, pain at the injection site.
Overdose (drug intoxication)
Symptoms: loss of appetite, gastralgia, diarrhea, nausea, vomiting (including blood), gastrointestinal bleeding, tachypnea, flushing of the facial skin, tachycardia, ventricular arrhythmias, insomnia, motor agitation, anxiety, photophobia, tremor, convulsions . In severe poisoning, epileptoid seizures may develop (especially in children without any warning signs), hypoxia, metabolic acidosis, hyperglycemia, hypokalemia, decreased blood pressure, skeletal muscle necrosis, confusion, renal failure with myoglobinuria.
Treatment: drug withdrawal, forced diuresis, hemosorption, plasma sorption, hemodialysis, symptomatic therapy. If convulsions occur, maintain airway patency and administer oxygen therapy. To relieve seizures - intravenous diazepam, 0.1-0.3 mg/kg (but not more than 10 mg). For severe nausea and vomiting, use metoclopramide or ondansetron (intravenously).
Eufillin - indications for use
Eufillin
- a pharmacological drug that is a combination of theophylline and ethylenediamine. The drug relieves spasms in the bronchi, blood vessels, and bile ducts. Eufillin is available in two forms: tablets and liquid ampoules.
There are a number of indications for the use of Eufillin:
- bronchospasms, asthma;
- apnea (impaired breathing function) in infants;
- cerebrovascular accident;
- angina pectoris and other cardiovascular diseases;
- diuretic for edema.
Eufillin for bronchitis
First of all, Eufillin is used to treat diseases of the respiratory system: asthma, bronchitis, chronic cough, emphysema. The drug makes breathing easier by opening the airways and providing more oxygen. The use of Eufillin should occur under strict medical supervision, since as a result of exceeding the dose, convulsions and rapid heartbeat may occur, and an insufficient amount of medication can aggravate the course of asthmatic attacks.
Dosage of Eufillin tablets
The dose of the drug and the frequency of its use are determined by the attending physician.
For respiratory diseases, the average daily dose for an adult is 300 mg, divided into two doses.
Patients with diseases of the cardiovascular system and weighing more than 60 kg are usually prescribed 400 mg of Euphyllin per day. People who weigh less should take 200 mg per day.
The daily dose may be reduced in case of severe heart and liver diseases, as well as in some viral diseases.
Children weighing up to 30 kg are prescribed no more than 20 mg per 1 kilogram of weight per day, dividing the dose into two doses.
Children under 7 years of age can take no more than 0.1 g of Euphyllin per 24 hours.
Attention!
For children under 3 years of age, the drug is prescribed in exceptional cases. The drug should not be given to infants under 3 months of age! During pregnancy, Eufillin can be used for edema.
Features of using Eufillin tablets:
- the drug cannot be taken with other medications;
- the medicine is not used for caffeine allergies;
- tablets should be taken with plenty of liquid;
- between doses it is necessary to maintain a period of at least 12 hours.
Eufillin - instructions for use of ampoules
The medicine is used intramuscularly for asthma. It is recommended to inject into the upper quadrant of the gluteal muscle in the amount of 100–500 mg per day. In some situations, adults can administer Eufillin into a vein at the rate of 6 mg of solution per 1 kg of weight. In case of severe asthmatic attacks, the patient is given a dropper of a solution of the drug (no more than 750 mg).
The amount of medication administered to the child is calculated by a specialist, taking into account the weight, age of the child and the pathology of the disease.
Eufillin for cellulite
Another direction of use of Eufillin is getting rid of cellulite. It is easy to prepare an anti-cellulite composition at home. One tablet of Eufillin is ground and mixed with Vaseline or baby cream. The resulting mixture not only reduces the “orange peel” effect, but also softens the skin and eliminates irritation. You can enhance the effect by using any anti-cellulite cream as a basis.
Efullin is used to combat cellulite manifestations and in the form of a wrap. A liquid preparation or cream is rubbed into problem areas, and the body is wrapped in cling film. Visible results are achieved after two weeks if daily procedures are performed. To enhance the effectiveness of the wrap, a mixture of massage cream, essential citrus oil (or tea tree oil), Dimexide and Euphyllin is prepared.
Interaction with other drugs
Ephedrine and caffeine enhance the effect of the drug.
Pharmaceutically incompatible with acid solutions.
Increases the likelihood of developing side effects of glucocorticosteroids, mineralocorticosteroids (hypernatremia), drugs for general anesthesia (increases the risk of ventricular arrhythmias), drugs that excite the central nervous system (increases neurotoxicity).
Antidiarrheal drugs and enterosorbents reduce the absorption of aminophylline.
Rifampicin, phenobarbital, phenytoin, isoniazid, carbamazepine, sulfinpyrazone,
aminoglutethimide, oral estrogen-containing contraceptives and moracizine, being inducers of microsomal oxidation, increase the clearance of aminophylline, which may require an increase in its dose.
When used simultaneously with macrolide antibiotics, lincomycin, allopurinol, cimetidine, isoprenaline, enoxacin, small doses of ethanol, disulfiram, fluoroquinolones, recombinant interferon alpha, methotrexate, mexiletine, propafenone, thiabendazole, ticlopidine, verapamil, and with influenza vaccination, the intensity of action of aminophylline may increase, which may require a reduction in its dose.
Enhances the effect of beta-adrenergic stimulants and diuretics (including by increasing glomerular filtration), reduces the effectiveness of lithium preparations and beta-blockers.
Compatible with antispasmodics, do not use in combination with other xanthine derivatives.
Prescribe with caution simultaneously with anticoagulants, with other theophylline or purine derivatives.
